HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on PDS Biotechnology (NASDAQ:PDSB) and maintained a $21 price target.
September 20, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PDS Biotechnology's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $21.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for PDS Biotechnology. The maintained price target of $21 indicates the firm's confidence in the company's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100